Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...

The Neuse-Pamlico Sound Women's Coalition is preparing for its 9th annual "March for Sickle Cell" 5K walk-run, an event aimed at raising awareness and funds to ...

IMMvention retained rights to use its technology to potentially pursue other targets, such as Parkinson’s or Alzheimer’s ...

Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, ...

Dr. Joseph Lubega calls sickle cell disease “probably the saddest story of a health problem that you could imagine.” He and ...

Washington University researchers found that sickle cell disease causes brains to appear 14 years older than their actual age ...

Statistics from the district health department indicate that in 2023, suspected cases of sickle cells stood at 1,456 and in ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

The CDC states that, on average, sickle cell disease reduces a patient's lifespan by more than 20 years, which is why Carla ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...